Skip to main content

Table 2 Prevalence of drug resistance among PLWH with virological failure on ART

From: Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study

 TDF + 3TC + NVP/EFVAZT + 3TC + NVP/EFVLPV/r + 3TC + AZT/TDFOthersTotal
n = 928 (%)n = 318 (%)n = 47 (%)N = 283 (%)N = 1576 (%)
PIs13 (1.40)9 (2.83)1 (2.13)6 (2.12)35 (2.22)
 ATV/r1 (0.35)2 (0.13)
 DRV/r
 FPV/r1 (0.31)1 (0.35)3 (0.19)
 IDV/r1 (0.35)2 (0.13)
 LPV/r1 (0.35)2 (0.13)
 NFV1 (0.11)1 (0.31)2 (0.71)6 (0.38)
 SQV/r1 (0.35)2 (0.13)
 TPV/r12 (1.29)8 (2.52)1 (2.13)5 (1.77)31 (1.97)
NRTIs97 (10.45)55 (17.30)2 (4.26)39 (13.78)232 (14.72)
 ABC92 (9.91)55 (17.30)2 (4.26)39 (13.78)227 (14.40)
 AZT26 (2.80)22 (6.92)2 (4.26)8 (2.83)66 (4.19)
 D4T44 (4.74)26 (8.18)2 (4.26)19 (6.71)110 (6.98)
 DDI45 (4.85)25 (7.86)2 (4.26)19 (6.71)110 (6.98)
 FTC91 (9.81)55 (17.30)2 (4.26)39 (13.78)226 (14.34)
 3TC91 (9.81)55 (17.30)2 (4.26)39 (13.78)226 (14.34)
 TDF30 (3.23)18 (5.66)1 (2.13)16 (5.65)81 (5.14)
NNRTIs269 (28.99)108 (33.96)10 (21.28)90 (31.80)567 (35.98)
 EFV261 (28.13)103 (32.39)10 (21.28)88 (31.10)550 (34.90)
 ETR63 (6.79)42 (13.21)1 (2.13)24 (8.48)154 (9.77)
 NVP261 (28.13)105 (33.02)10 (21.28)88 (31.10)552 (35.03)
 RPV96 (10.34)58 (18.24)1 (2.13)35 (12.37)225 (14.28)
  1. TDF Tenofovir, 3TC Lamivudine, NVP Nevirapine, EFV Efavirenz, AZT Zidovudine, LPV/r Fosamprenavir/ritonavir, ATV/r Atazanavir/ritonavir, DRv/r Darunavir/ritonavir, FPV/r Fosamprenavir/ritonavir, IDV/r Indinavir/Ritonavir, NFV Nelfinavir, SQV/r Ritonavir-boosted saquinavir, TPV/r Tipranavir/ritonavir, ABC Abacavir, D4T Stavudine, DDI Didanosine, FTC Emtricitabine, ETR Etravirine, RPV Rilpivirine